https://allsci.com/news/research/tauopathy-treatment-washu-researchers-show/ AllScien 2026-10-05T13:22:38.000599Z WashU researchers show blocking T-cell brain entry protects against tau-driven damage in mice https://allsci.com/news/licensing-and-partnerships/sleep-disorder-drug-nhwa-licenses-to-somnivera/ AllScien 2026-10-05T13:13:53.726725Z Nhwa licenses sleep-disorder drug to Somnivera for up to USD 517.5m outside Greater China https://allsci.com/news/biotech/2026-nobel-prize-karolinska-institutet-awards-in/ AllScien 2026-10-05T13:07:36.317668Z 2026 Nobel medicine prize honors Deisseroth, Hegemann and Nagel for optogenetics https://allsci.com/news/clinical-trials/dmd-treatment-ractigens-rag-18-triggers-utrophin/ AllScien 2026-10-05T12:32:42.385156Z Ractigen’s RAG-18 triggers utrophin upregulation in first-in-human DMD data https://allsci.com/news/biotech/platinum-resistant-ovarian-cancer-rina-s-delivers/ AllScien 2026-10-05T12:29:03.434035Z Rina-S delivers 46% response rate and 12-month durability in platinum-resistant ovarian cancer https://allsci.com/news/approvals/jaypirca-cll-approval-fda-expands-into-first-line/ AllScien 2026-10-05T12:12:14.675348Z Jaypirca breaks into first-line CLL/SLL with FDA approval https://allsci.com/news/licensing-and-partnerships/hunter-syndrome-italfarmaco-licenses-jcrs/ AllScien 2026-10-05T11:16:51.579041Z Italfarmaco licenses JCR's brain-penetrating Hunter syndrome therapy for US, Europe and Latin America https://allsci.com/news/biotech/pompe-disease-five-year-propel-data-show/ AllScien 2026-10-05T11:08:30.251262Z BioMarin reports durable five-year outcomes with Pombiliti/Opfolda in late-onset Pompe disease https://allsci.com/news/cancer-death-rates-cdc-nci-acs-and-naaccr-report/ AllScien 2026-10-05T10:12:25.611763Z Annual US cancer report finds lung cancer gains driving two-decade decline in deaths https://allsci.com/news/research/cdk46-inhibitor-resistance-boston-childrens/ AllScien 2026-10-05T10:08:41.253941Z Boston Children’s researchers uncover nuclear FAH role in CDK4/6-resistant breast cancer https://allsci.com/news/licensing-and-partnerships/lixudebart-deal-csl-bets-usd-355m-upfront-on/ AllScien 2026-10-05T09:54:59.449315Z CSL bets USD 355m upfront on Alentis' claudin-1 antibody lixudebart in rare kidney and liver diseases https://allsci.com/news/biotech/celaid-therapeutics-secures-jpy-400m-second-close/ AllScien 2026-10-05T09:53:45.784718Z Japan's Celaid raises JPY 400m as lead stem-cell therapy heads towards US trial https://allsci.com/news/biotech/denecimig-approval-fda-manufacturing-review/ AllScien 2026-10-05T09:43:50.804187Z US FDA delays review of Novo hemophilia drug denecimig over manufacturing issue https://allsci.com/news/biotech/sbma-treatment-annji-advances-aj201-into-phase/ AllScien 2026-10-05T09:24:34.428944Z AnnJi advances androgen receptor-clearing rosolutamide into Phase III for Kennedy’s disease https://allsci.com/news/biotech/tre-515-fast-track-fda-grants-designation-kras/ AllScien 2026-10-05T08:59:51.897575Z Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination https://allsci.com/news/clinical-trials/cutaneous-lupus-biogens-litifilimab-shows/ AllScien 2026-10-05T08:21:32.038745Z Biogen’s litifilimab builds momentum with durable 52-week responses in CLE